Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report)’s stock price rose 3.6% on Friday . The company traded as high as $1.17 and last traded at $1.14. Approximately 97,603 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 290,582 shares. The stock had previously closed at $1.10.
Evaxion Biotech A/S Price Performance
The company has a market capitalization of $31.77 million, a P/E ratio of -1.16 and a beta of 0.35. The stock’s fifty day simple moving average is $0.82 and its 200-day simple moving average is $1.15. The company has a debt-to-equity ratio of 3.95, a current ratio of 2.81 and a quick ratio of 2.81.
Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 22nd. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. On average, equities analysts forecast that Evaxion Biotech A/S will post -0.82 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Evaxion Biotech A/S
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.
- Five stocks we like better than Evaxion Biotech A/S
- Stock Sentiment Analysis: How it Works
- Shocking uranium play that hedge funds kept hidden
- Where Do I Find 52-Week Highs and Lows?
- Dependable dividends: Why utility stocks are on fire
- How to Calculate Stock Profit
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.